Latest News on INSP

Financial News Based On Company


Advertisement
Advertisement

Inspire Medical Systems (INSP) Faces A Fresh Europe Patent Test As Valuation Debate Continues

https://sg.finance.yahoo.com/news/inspire-medical-systems-insp-faces-091722460.html
Inspire Medical Systems (INSP) is facing a new legal challenge in Europe after a default decision favored rival Nyxoah in a patent dispute. This legal setback adds to a period of weak share price performance for the company. While analysts on Simply Wall St see the stock as 13% undervalued, a discounted cash flow model suggests it might be slightly expensive, leading to mixed signals for investors.

Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case

https://uk.finance.yahoo.com/news/nyxoah-obtains-default-decision-against-070000458.html
Nyxoah SA announced that the Unified Patent Court (UPC) in Munich, Germany, issued a default decision in its favor in an infringement case against Inspire Medical Systems. The case concerned Nyxoah's European Patent 2 760 534, and Nyxoah is now evaluating options for enforcement. The company specializes in the Genio system, a hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA).

A Munich court issued a default decision for Nyxoah in its patent case against Inspire Medical Systems.

https://www.stocktitan.net/news/NYXH/nyxoah-obtains-default-decision-against-inspire-medical-systems-in-otdf3y65r2l1.html
Nyxoah (NYXH) has obtained a default decision in its favor against Inspire Medical Systems from the Unified Patent Court's Court of First Instance in Munich, Germany. The infringement case concerned Nyxoah’s European Patent 2 760 534, and the company is now considering all enforcement options. This development is significant for Nyxoah, a medical technology company specializing in treatments for Obstructive Sleep Apnea.

Inspire Medical Systems, Inc. to Present at the Piper Sandler 38th Annual Healthcare Conference

https://www.manilatimes.net/2026/11/18/tmt-newswire/globenewswire/inspire-medical-systems-inc-to-present-at-the-piper-sandler-38th-annual-healthcare-conference/2472546
Inspire Medical Systems, Inc. announced its management team will present at the Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1, 2026, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available, with a replay accessible for two weeks afterward on Inspire's investor website. Inspire focuses on innovative, minimally invasive solutions for obstructive sleep apnea.

A live stream will carry Inspire Medical Systems' conference presentation Dec. 1 at 3 p.m. Eastern time.

https://www.stocktitan.net/news/INSP/inspire-medical-systems-inc-to-present-at-the-piper-sandler-38th-bxsdapa1vw3h.html
Inspire Medical Systems (NYSE: INSP) announced that its management team will present at the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available, with a replay accessible for two weeks afterward on the company's investor website. The company specializes in innovative, minimally invasive solutions for obstructive sleep apnea.
Advertisement

AQR reports shared voting power over 839,258 shares in Inspire Medical Systems (INSP).

https://www.stocktitan.net/sec-filings/INSP/schedule-13g-a-inspire-medical-systems-inc-amended-passive-investment-7cb1b8ebe07b.html
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have filed an amended ownership report for Inspire Medical Systems, Inc. (INSP). As of September 30, 2026, each entity reported beneficial ownership of 839,258 shares, representing a 2.90% stake in the company. Both entities also reported shared voting and dispositive power over these 839,258 shares.

INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

https://www.tradingview.com/news/zacks:c7d8bba59094b:0-insp-is-up-12-1-in-three-months-can-its-rally-continue-from-here/
Inspire Medical Systems (INSP) shares have risen 12.1% in the past three months despite ongoing reimbursement issues. While Q3 2026 revenues and adjusted EPS declined year-over-year, they still surpassed Zacks Consensus Estimates and showed sequential improvement. The company's 2027 recovery plan, Project Horizon, focuses on patient engagement and education to stabilize growth, with valuation suggesting potential for multiple expansion if these efforts succeed.

Inspire Medical Systems (NYSE:INSP) Strong Profits May Be Masking Some Underlying Issues

https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/inspire-medical-systems-nyseinsp-strong-profits-may-be-maski
Inspire Medical Systems' recent earnings report, while seemingly solid, has investors concerned due to underlying factors. The company incurred a US$20m expense from unusual items but also benefited from a US$70m tax benefit, which may temporarily inflate statutory profit. These contrasting influences make it unclear if the reported profits truly reflect the company's sustainable earnings potential.

Stocks making big moves this week: Sprout Social, Redwire, Inspire Medical Systems, Fastly, and Marvell Technology

https://ca.finance.yahoo.com/news/stocks-making-big-moves-week-022936540.html
This article highlights several companies whose stocks experienced significant movement this week following their latest financial reports or major announcements. Sprout Social, Redwire, Inspire Medical Systems, and Fastly all saw their stock prices fall after reporting third-quarter results that either missed analyst estimates, showed a net loss, or failed to impress. Marvell Technology's stock also declined after it announced an agreement to acquire Lumentum in an all-stock transaction.

Inspire Medical Systems, Inc. (INSP) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/INSP/seasonality/
The article provides a seasonal returns chart for Inspire Medical Systems, Inc. (INSP). However, it notes that seasonality data is currently unavailable for INSP. The page also displays the current stock price and trading information for INSP.
Advertisement

Inspire Medical Systems Inc (INSP) Q3 2026 Earnings Call Highlights: Revenue Slips 7. ...

https://sg.finance.yahoo.com/news/inspire-medical-systems-inc-insp-190132369.html
Inspire Medical Systems Inc. reported Q3 2026 revenue of $206.7 million, a 7.9% year-over-year decline, though adjusted operating income exceeded expectations. The company faced significant headwinds from coding and reimbursement changes, estimated at $120 million for the full year, but expects a return to low single-digit revenue growth in 2027 driven by a stable coding environment and growth investments. FDA approval for a Category 1 CPT code for Inspire 5, effective 2028, is anticipated to simplify reimbursement and expand access.

STAAR Surgical, Integra LifeSciences, Envista, LeMaitre, and Inspire Medical Systems stocks trade up, what you need to know

https://www.tradingview.com/news/stockstory:7319cb925094b:0-staar-surgical-integra-lifesciences-envista-lemaitre-and-inspire-medical-systems-stocks-trade-up-what-you-need-to-know/
Several medical device and supplies stocks, including STAAR Surgical, Integra LifeSciences, Envista, LeMaitre, and Inspire Medical Systems, saw significant gains after election results confirmed Democrats reclaiming majorities in Congress. This outcome eased regulatory uncertainty surrounding drug pricing policy, which analysts project will strengthen the biopharmaceutical sector's recovery. The broader market also rebounded, viewing congressional checks and balances as a stabilizing force for policy decisions.

STAAR Surgical, Integra LifeSciences, Envista, LeMaitre, and Inspire Medical Systems stocks trade up, what you need to know

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-4-staar-surgical-integra-lifesciences-envista-lemaitre-and-inspire-medical-systems-stocks-trade-up-what-you-need-to-know
Several medical device and supply stocks, including STAAR Surgical, Integra LifeSciences, Envista, LeMaitre, and Inspire Medical Systems, saw significant gains after election results confirmed Democratic majorities in Congress. This outcome eased regulatory uncertainty regarding drug pricing policy, which analysts believe will strengthen the biopharmaceutical sector's recovery. The broader market also rebounded as investors viewed the congressional checks and balances as a stabilizing force for executive policy decisions.

Baird maintains Inspire Medical Systems at Neutral, raises price target to $77 from $73

https://www.tradingview.com/news/tradingview:d9fcad31bcbcf:0-baird-maintains-inspire-medical-systems-at-neutral-raises-price-target-to-77-from-73/
Baird has reiterated its "Neutral" rating for Inspire Medical Systems (INSP) and increased its price target to $77 from $73, representing a 5.5% raise. This new price target suggests a potential upside of 14.6% from the stock's closing price of $67.21 on November 2nd. The article advises readers to explore further price target data and analyst ratings on the Forecasts tab and track recommendations in the News Flow.

Inspire Medical Systems (INSP) Stock Slides As Q3 Earnings Turn Lossmaking

https://uk.finance.yahoo.com/news/inspire-medical-systems-insp-stock-043258572.html
Inspire Medical Systems (INSP) reported a challenging Q3 2026, with revenue declining to US$206.7m and basic EPS flipping to a loss of US$0.84, resulting in a net loss of US$24.4m. This profitability squeeze caused the stock to drop 7.9% to US$61.90, signaling investor concern about the company's ability to maintain growth amid reimbursement pressures. The company's execution on Project Horizon aims to offset these challenges, but immediate impacts on patient flow and procedure efficiency have not yet materialized.
Advertisement

These Analysts Increase Their Forecasts On Inspire Medical After Strong Q3 Results

https://www.benzinga.com/analyst-stock-ratings/price-target/26/11/62817057/these-analysts-increase-their-forecasts-on-inspire-medical-after-strong-q3-results
Inspire Medical Systems (NYSE: INSP) reported strong third-quarter earnings, beating analyst estimates for both EPS and sales. Following these upbeat results, the company narrowed its full-year 2026 guidance. Consequently, several analysts, including those from Baird and Piper Sandler, raised their price targets on Inspire Medical.

Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference

https://finance.yahoo.com/healthcare/articles/inspire-medical-systems-inc-present-210500004.html
Inspire Medical Systems, Inc. (NYSE: INSP) announced that its management team will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026, at 2:40 p.m. Eastern Time. A live webcast of the presentation will be available, with a replay accessible for two weeks afterward on the company's investor website. Inspire is a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea.

A sleep apnea technology company is scheduled to present at a healthcare conference Nov. 10.

https://www.stocktitan.net/news/INSP/inspire-medical-systems-inc-to-present-at-the-stifel-2026-healthcare-89ejsonzkqqb.html
Inspire Medical Systems (NYSE: INSP) announced that its management will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 2:40 p.m. Eastern Time. The presentation will be webcast live, and a replay will be available for two weeks on Inspire’s investor website. Inspire specializes in innovative, minimally invasive solutions for patients with obstructive sleep apnea.

Why Inspire Medical Systems (INSP) stock is down today

https://www.tradingview.com/news/stockstory:1030c1ccb094b:0-why-inspire-medical-systems-insp-stock-is-down-today/
Shares of Inspire Medical Systems (INSP) fell 8.2% after the company reported a third-quarter net loss of $24.4 million and narrowed its full-year revenue guidance. Revenue decreased 7.9% year-on-year to $206.7 million due to coding and reimbursement difficulties in the United States, although both revenue and adjusted EPS were above analyst estimates. Despite the current dip, the stock had previously seen a significant gain after CMS finalized increased payment rates for its sleep apnea procedures, a key catalyst as Medicare accounts for a substantial portion of its patient mix.

Wells Fargo maintains Inspire Medical Systems at Equal-Weight, raises price target to $69 from $56

https://www.tradingview.com/news/tradingview:abd0ef5686a6e:0-wells-fargo-maintains-inspire-medical-systems-at-equal-weight-raises-price-target-to-69-from-56/
Wells Fargo has reaffirmed its "Equal-Weight" rating on Inspire Medical Systems (INSP) and increased its price target from $56 to $69, representing a 23.2% rise. This new target suggests a modest 2.7% upside from the stock's closing price of $67.21 on November 2nd. The article also provides a summary of recent analyst actions and price targets for Inspire Medical Systems from other firms.
Advertisement

Inspire Medical Systems Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:679f43754094b:0-inspire-medical-systems-q3-earnings-call-highlights/
Inspire Medical Systems reported Q3 revenue of $206.7 million, a 7.9% year-over-year decrease but a 3% sequential increase, driven by strong U.S. performance offsetting weaker international results. The company addressed ongoing coding and reimbursement challenges, expressing confidence in their resolution and providing an updated full-year outlook. Inspire is also progressing with new CPT codes for 2028 and developing its next-generation Inspire VI device, targeting a 2027 FDA submission.

Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results

https://www.manilatimes.net/2026/11/03/tmt-newswire/globenewswire/inspire-medical-systems-inc-announces-third-quarter-2026-financial-results/2460054
Inspire Medical Systems, Inc. reported its third quarter 2026 financial results, with revenue decreasing 7.9% to $206.7 million due to U.S. coding and reimbursement challenges. Despite a net loss of $24.4 million, the company showed sequential growth and positive operating cash flow of $46.4 million. Inspire also announced the AMA CPT® Editorial Panel's approval of new Category I CPT codes for single lead hypoglossal nerve stimulation, including Inspire V, set to take effect January 1, 2028, which is expected to enhance clarity and patient access.

Form 8K Inspire Medical Systems Inc For: 2 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-inspire-medical-systems-inc-for-2-november-93CH-4950473
This article announces that Inspire Medical Systems Inc. filed a Form 8K on November 2nd. The brief report from Investing.com indicates this as a company news item related to stock markets. The content is essentially a placeholder for the Form 8K filing, highlighting the company and the date of the filing.

Inspire Medical Systems | 8-K: Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results

https://www.moomoo.com/news/notice/1003235860/inspire-medical-systems-inc-announces-third-quarter-2026-financial-results
Inspire Medical Systems, Inc. announced its financial results for the third quarter of 2026. This 8-K filing indicates a formal disclosure of the company's performance during this period. The announcement likely includes key financial metrics and operational highlights for the quarter.

Inspire Medical Systems Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62804801/inspire-medical-systems-q3-2026-earnings-call-transcript
Inspire Medical Systems reported a 7.9% year-over-year revenue decrease in Q3 2026, though revenue increased 3% sequentially, driven by strong U.S. performance. The company is addressing coding challenges with a new billing framework and anticipates a significant reimbursement increase, with a Category 1 CPT code effective January 2028 simplifying long-term coding. Strategic initiatives like Project Horizon reallocate $30 million to expand market access and patient flow, supported by growing clinical evidence for Inspire Therapy's efficacy and broader health benefits beyond sleep apnea.
Advertisement

Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance

https://www.streetinsider.com/Earnings/Inspire+Medical+Systems+%28INSP%29+Tops+Q3+EPS+by+5c%2C+Beats+on+Revenue%3B+Offers+FY26+Guidance/27274689.html
Inspire Medical Systems (NYSE: INSP) reported strong third-quarter results, surpassing analyst estimates with EPS of $0.14 on revenue of $206.7 million. The company also provided its fiscal year 2026 guidance, projecting EPS between $1.20 and $1.40, and revenue ranging from $850 million to $860 million, which aligns with the consensus estimate.

Inspire Medical Systems Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:721964:0-inspire-medical-systems-q3-2026-earnings-call-is-live/
Inspire Medical Systems' (INSP) Q3 2026 earnings call has commenced, where executives will discuss the latest financial results and answer questions from Wall Street analysts. This event is crucial for followers of INSP, as management commentary on future demand, margins, or capital spending can significantly impact market movements.

Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results

https://au.finance.yahoo.com/news/inspire-medical-systems-inc-announces-212800644.html
Inspire Medical Systems (NYSE: INSP) reported its Q3 2026 financial results, with revenue decreasing 7.9% to $206.7 million, primarily due to U.S. coding and reimbursement challenges. Despite a net loss of $24.4 million, the company showed sequential growth in U.S. performance and narrowed its full-year 2026 revenue guidance to $850 million to $860 million. The AMA CPT® Editorial Panel's approval of new Category I CPT codes for single lead hypoglossal nerve stimulation, including Inspire V, effective January 1, 2028, is expected to enhance clarity and patient access.

Inspire Medical Systems (NYSE:INSP) beats Q3 2026 sales expectations

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-2-inspire-medical-systems-nyseinsp-beats-q3-2026-sales-expectations
Inspire Medical Systems (NYSE:INSP) reported Q3 2026 results that exceeded analysts' revenue and adjusted EPS expectations, despite a 7.9% year-on-year decline in revenue to $206.7 million. The company reconfirmed its full-year revenue guidance of $855 million and raised its full-year adjusted EPS guidance by 4% to $1.30. Shares edged lower by 1.4% immediately after the results were released, suggesting the market had hoped for more.

Why (INSP) Price Action Is Critical for Tactical Trading

https://news.stocktradersdaily.com/news_release/24/Why_INSP_Price_Action_Is_Critical_for_Tactical_Trading_110226123402_1793597642.html
This article analyzes Inspire Medical Systems Inc. (NASDAQ: INSP), highlighting weak near-term sentiment and a critical resistance test. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for various time horizons. The analysis also identifies an exceptional 110.1:1 risk-reward short setup.
Advertisement

Inspire Medical Systems earnings: what to look for from INSP

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-1-inspire-medical-systems-earnings-what-to-look-for-from-insp
Inspire Medical Systems (NYSE: INSP) is set to report its earnings after market close tomorrow, with analysts expecting an 8.9% year-on-year revenue decline. The company previously exceeded revenue and EPS expectations last quarter, and analysts have largely maintained their estimates. While the healthcare equipment and supplies segment has seen positive investor sentiment, Inspire Medical Systems' stock has been down 3.8% over the last month.

Vanguard reports an Inspire Medical Systems (INSP) stake with voting power over 36,509 shares.

https://www.stocktitan.net/sec-filings/INSP/schedule-13g-a-inspire-medical-systems-inc-amended-passive-investment-ba28136adda1.html
Vanguard Portfolio Management has reported a beneficial ownership of 1,741,113 shares of Inspire Medical Systems, Inc. (INSP) common stock, which represents 6.02% of the class. The firm holds sole voting power over 36,509 shares and sole dispositive power over all 1,741,113 shares. This disclosure was made in an amended passive investment filing (SCHEDULE 13G/A).

Inspire Medical Systems Inc. Financials | INSP

https://www.barrons.com/market-data/stocks/insp/financials?ocid=msedg%252Fcountry%252Fhong-kong%252F1&mod=quotes
This article provides detailed financial information for Inspire Medical Systems Inc. (INSP), including analyst ratings, stock performance metrics, and comprehensive income statement data from 2021 to 2025. The company specializes in minimally invasive solutions for obstructive sleep apnea. Financial trends show significant sales and net income growth over the five-year period.

Inspire Medical Systems, Inc. Estimates – NYSE:INSP

https://www.tradingview.com/symbols/NYSE-INSP/financials-estimates/
This article provides an overview of Inspire Medical Systems, Inc. (NYSE: INSP) financial estimates available on TradingView. It highlights where users can explore reported financial data and analyst estimates, comparing actual results with average, high, and low estimates across various financial statements and valuation metrics. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.

Inspire Medical Systems Inc. (US4577301090.SG) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/US4577301090.SG/sec-filing/
The article provides an overview of Inspire Medical Systems Inc. (US4577301090.SG) stock on Yahoo Finance, showing its current price of 63.50 EUR and a 1.55% decrease. It offers various data points such as news, charts, statistics, historical data, and financial analysis. The content is primarily a stock quote page with basic company information.
Advertisement

Is Inspire Medical Systems (INSP) Fully Valued As Shares Trade Above Fair Value?

https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/is-inspire-medical-systems-insp-fully-valued-as-shares-trade
Inspire Medical Systems (INSP) shares recently closed at $72.66, above its fair value estimate of $68.00, suggesting it may be overvalued by 6.9%. While short-term momentum is strong, longer-term returns have declined. Analyst narratives point to overvaluation based on fundamental assumptions, yet multiples suggest potential underpricing compared to industry averages.

InvestingPro’s fair value spotted 70% gain in Inspire Medical stock By Investing.com

https://www.investing.com/news/investment-ideas/investingpros-fair-value-spotted-70-gain-in-inspire-medical-stock-93CH-4959678
InvestingPro's Fair Value analysis successfully identified Inspire Medical Systems (INSP) as significantly undervalued in May 2026, predicting a substantial upside. The stock subsequently surged nearly 70% in four months, validating the analytical models. As of October 2026, InvestingPro still sees an additional 14% upside for INSP.

Form 4 Inspire Medical Systems Inc: Georgia Melenikiotou (Director) For: 14 October

https://ca.investing.com/news/stock-market-news/form-4-inspire-medical-systems-inc-georgia-melenikiotou-director-for-14-october-93CH-4886198
This article reports on a Form 4 filing for Inspire Medical Systems Inc, indicating insider activity by director Georgia Melenikiotou on October 14. Form 4 filings are regulatory documents that disclose changes in stock ownership by company insiders. The specific details of the transaction are not provided within the snippet.

A director receives 203 shares instead of cash fees at Inspire Medical Systems (INSP).

https://www.stocktitan.net/sec-filings/INSP/form-4-inspire-medical-systems-inc-insider-trading-activity-4822297f3bce.html
Michael H. Carrel, a director at Inspire Medical Systems, acquired 203 shares of common stock on October 14, 2026, as compensation instead of cash fees, with each share valued at $68.07. Following this transaction, his direct holdings in the company increased to 5,834 shares. This transaction was carried out under the company's Non-Employee Director Compensation Policy.

A director receives 284 shares instead of cash fees at Inspire Medical Systems (INSP)

https://www.stocktitan.net/sec-filings/INSP/form-4-inspire-medical-systems-inc-insider-trading-activity-47335bac862c.html
Shelley G. Broader, a director at Inspire Medical Systems, Inc. (INSP), acquired 284 shares of common stock on October 14, 2026. This acquisition was made in lieu of cash fees, under the company's Non-Employee Director Compensation Policy. The transaction price was reported as $68.07 per share, bringing her direct holdings to 9,138 shares after the acquisition.
Advertisement

A director receives 255 shares instead of cash fees at Inspire Medical Systems (INSP).

https://www.stocktitan.net/sec-filings/INSP/form-4-inspire-medical-systems-inc-insider-trading-activity-4e7230b251d7.html
Inspire Medical Systems director Georgia Melenikiotou received 255 shares of common stock on October 14, 2026, as part of the company's Non-Employee Director Compensation Policy, in lieu of cash fees. The shares were valued at $68.07 each, and following this transaction, Ms. Melenikiotou directly holds 8,584 shares of the company. This transaction was reported in a Form 4 SEC filing on October 16, 2026.

A director receives 431 shares instead of cash fees at Inspire Medical Systems (INSP).

https://www.stocktitan.net/sec-filings/INSP/form-4-inspire-medical-systems-inc-insider-trading-activity-860c2044d1b7.html
Inspire Medical Systems director Gary Lee Ellis received 431 shares of common stock on October 14, 2026, in lieu of cash fees, as per the company’s Non-Employee Director Compensation Policy. The shares were valued at $68.07 each, bringing his direct holdings to 11,850 shares after the transaction. This transaction was reported in a Form 4 SEC filing.

Truist Securities Adjusts Inspire Medical Systems PT to $78 From $62, Maintains Hold Rating

https://finance.yahoo.com/markets/stocks/articles/truist-securities-adjusts-inspire-medical-122033699.html
Truist Securities has revised its price target for Inspire Medical Systems (INSP) to $78, an increase from the previous $62. Despite this adjustment, the firm has chosen to maintain a Hold rating on the stock. The article mentions that Inspire Medical Systems currently has an average hold rating and a mean price target of $65 according to MT Newswires data.

Inspire Medical Systems (INSP) After New CPT Codes With A Slightly Pricey Valuation

https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/inspire-medical-systems-insp-after-new-cpt-codes-with-a-slig
Inspire Medical Systems (INSP) recently secured regulatory approval for new Category I CPT codes for its Inspire V system, effective January 2028, a milestone that could simplify billing and improve revenue. Despite this positive development and recent share price momentum, the stock is considered 8% overvalued at US$68.89 compared to a narrative fair value of $63.80. However, an analysis of its P/E ratio suggests the market might be pricing in execution risk, as it trades at 14.7x earnings against an industry average of 24.2x.

Mizuho Securities Maintains Inspire Medical Systems(INSP.US) With Buy Rating, Raises Target Price to $75

https://www.moomoo.com/news/post/1001042994/mizuho-securities-maintains-inspire-medical-systems-inspus-with-buy-rating
Mizuho Securities has reiterated its Buy rating on Inspire Medical Systems (INSP.US) and increased its price target to $75. This adjustment reflects the firm's continued confidence in the company's performance and future outlook.
Advertisement

Free cash flow per share of Inspire Medical Systems, Inc. – HAM:2DR

https://www.tradingview.com/symbols/HAM-2DR/financials-statistics-and-ratios/free-cash-flow-per-share/
This article provides access to the free cash flow per share data for Inspire Medical Systems, Inc. (HAM:2DR) on the TradingView platform. It highlights that the market for this stock on the Hamburg Stock Exchange is currently closed with no trades recorded. The data is made available through TradingView's financial tools.

Learn Why The Bull Case For Inspire Medical Systems (INSP) Could Change Following Shareholder Investigation

https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/learn-why-the-bull-case-for-inspire-medical-systems-insp-cou
Inspire Medical Systems is facing a shareholder investigation concerning alleged misleading statements regarding its Inspire V product demand, inventory, launch readiness, and Medicare reimbursement. This legal scrutiny adds complexity to the company's operational narrative, even as the AMA has approved new Category I CPT codes for Inspire V taking effect in 2028, which could eventually clarify reimbursement. The situation highlights the importance of execution, governance, and coding economics for Inspire Medical Systems, with analysts projecting significant revenue and earnings changes by 2029.

Price to cash flow ratio of Inspire Medical Systems, Inc. – HAN:2DR

https://www.tradingview.com/symbols/HAN-2DR/financials-statistics-and-ratios/price-cash-flow/
This article provides financial information for Inspire Medical Systems, Inc. (HAN:2DR) on the Hannover Stock Exchange. It specifically highlights the company's price to cash flow ratio. The content appears to be a financial data page from TradingView.

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Picard Medical, Inc. (PMI), Methode Electronics, Inc. (MEI), Inspire Medical Systems, Inc. (INSP), and GRAIL, Inc. (GRAL)

https://www.globenewswire.com/news-release/2026/10/09/3378244/0/en/johnson-fistel-pllp-investigates-claims-on-behalf-of-long-term-shareholders-of-picard-medical-inc-pmi-methode-electronics-inc-mei-inspire-medical-systems-inc-insp-and-grail-inc-gra.html
Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Picard Medical, Inc. (PMI), Methode Electronics, Inc. (MEI), Inspire Medical Systems, Inc. (INSP), and GRAIL, Inc. (GRAL). The investigations focus on alleged breaches of fiduciary duty by officers and directors, stemming from previously filed securities class action complaints. Shareholders who have continuously held shares since specified dates are encouraged to contact the firm to learn about seeking corporate governance reforms and potential recovery of funds.

Inspire Medical Systems Price Target Announced at $65.00/Share by Barclays

https://www.moomoo.com/news/post/1000694274/inspire-medical-systems-price-target-announced-at-65-00-share
Barclays has set a price target of $65.00 per share for Inspire Medical Systems. This target provides investors with an updated valuation perspective on the company.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement